𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Juvenile toxicity assessment of d,l-methylphenidate in rats

✍ Scribed by David A. Beckman; Marilynn Schneider; Maureen Youreneff; Francis L.S. Tse


Publisher
John Wiley and Sons
Year
2008
Tongue
English
Weight
174 KB
Volume
83
Category
Article
ISSN
1542-9733

No coin nor oath required. For personal study only.

✦ Synopsis


Abstract

BACKGROUND: The oral administration of d,l‐methylphenidate (MPH) was designed to encompass the major part of postnatal development in the rat and to evaluate potential chronic effects. METHODS: Wistar Hannover rats were cross‐fostered on postpartum day 0 (day of birth) and were administered MPH at doses of 5, 50, and 100 mg/kg/day (mpkd) on postpartum days 7 to 70. Clinical signs, body weight, food consumption, developmental, behavioral, clinical/anatomic pathology, toxicokinetic, and fertility evaluations were conducted. RESULTS: MPH‐related effects on clinical signs, body weight, and behavior tests were noted. Increased locomotor activity and cage biting/chewing occurred at ≥5 mpkd (females) and ≥50 mpkd (males) and were absent after dosing ceased. Body weight parameters were decreased at ≥50 mpkd and were comparable to controls at 5 weeks' recovery. Open field motor activity tests conducted 2 weeks after dosing ceased revealed decreased peripheral beam breaks at ≥50 mpkd. Passive avoidance tests conducted 3 weeks after dosing ceased indicated decreased females reaching learning criterion at 100 mpkd. This is considered of nominal significance as there were no effects in the water maze test or retention in passive avoidance test. After multiple doses, females exhibited higher exposures than males and exposures were reduced in all groups in comparison to those after a single dose. CONCLUSIONS: These results suggest that MPH can produce enduring behavioral effects in rats. The no‐toxicologic‐effect‐level was 5 mpkd, associated with AUC~(0–24 h)~ racemate values in males and females, respectively, of 101 and 153 ng.h/mL after chronic dosing. Birth Defects Res (Part B) © 2008 Wiley‐Liss, Inc.


📜 SIMILAR VOLUMES


D-methylphenidate and D,L-methylphenidat
✍ Steve K. Teo; David I. Stirling; Alan M. Hoberman; Mildred S. Christian; Steve D 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 136 KB 👁 1 views

## Abstract **BACKGROUND:** D,L‐__threo__‐Methylphenidate (D,L‐MPH) is marketed currently for attention deficit hyperactivity disorder in children. D‐__threo__‐methylphenidate (dexmethylphenidate; D‐MPH) is a refined formulation of D,L‐methylphenidate containing only the active enantiomer and was r

Toxicokinetic assessment of methylphenid
✍ Ray Bakhtiar; Francis L. S. Tse 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 117 KB

Ritalin or methylphenidate (MPH) is prescribed for the treatment of attention deficit hyperactivity disorder (ADHD) and narcolepsy. The present report describes the determination of plasma concentrations of D-threo- and L-threo-enantiomers of MPH in toxicokinetic (TK) studies in pregnant Wistar Hann

Toxicokinetic assessment of methylphenid
✍ Ray Bakhtiar; Luis Ramos; Francis L. S. Tse 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 167 KB

## Abstract Ritalin^®^ or methylphenidate (MPH) is often prescribed for the treatment of attention deficit hyperactivity disorder (ADHD) and narcolepsy. The therapeutic activity of MPH is principally due to d‐__threo__‐[2__R__,2′__R__]‐MPH. Hence, in order to establish a kinetic relationship between

Reproductive toxicity assessment of laso
✍ Gregg D. Cappon; Masao Horimoto; Mark E. Hurtt 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 114 KB

## Abstract **BACKGROUND:** Lasofoxifene is a nonsteroidal selective estrogen receptor modulator (SERM) with greater than 100‐fold selectivity against all other steroid receptors and is a potentially superior treatment for postmenopausal osteoporosis. The purpose of this study was to evaluate the e